文献速递艾滋病与性传播感染

在HIV治愈临床试验设计中平衡统计效力与风险

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
PubMed 文献 · J Infect Dis · 2022-01-01

该研究用数学模型基于既往观察到的 analytical treatment interruption(ATI)后病毒反弹时间(TVR)动力学,模拟安慰剂对照TVR研究所需样本量、检测频率和ATI持续时间。结果显示每组需120例才能在80%效力下检出病毒再激活频率30%的差异,且每周检测病毒载量或ATI超过5周无统计学优势。作者认为当前TVR治愈研究统计效力不足,替代设计可提高效力。

要点

  • 安慰剂对照TVR研究每组需120例,80%效力下检出病毒再激活频率30%差异。
  • 每周检测病毒载量或ATI超过5周在TVR研究中无统计学优势。
  • 当前TVR HIV治愈研究统计效力不足以检出病毒再激活频率的统计学显著变化。

核心结论

  • 当前TVR HIV治愈研究统计效力不足以检出病毒再激活频率的统计学显著变化。
  • 替代研究设计可提高ATI试验的统计效力。

研究设计与样本

  • 使用数学模型,基于既往观察到的ATI后病毒反弹时间(TVR)动力学,模拟最优样本量、检测频率和ATI持续时间。
  • 使用log-rank检验以及分析和随机技术比较对照组与干预组。

主要发现

  • 在安慰剂对照TVR研究中,每组需要120例受试者,才能在80%效力下检出病毒再激活频率30%的差异。
  • 在TVR研究中,检测病毒载量频率高于每周一次或ATI超过5周几乎没有统计学优势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Analytical treatment interruptions (ATI) are pauses of antiretroviral therapy (ART) in the context of human immunodeficiency virus (HIV) cure trials. They are the gold standard in determining if interventions being tested can achieve sustained virological control in the absence of ART. However, withholding ART comes with risks and discomforts to trial participant. We used mathematical models to explore how ATI study design can be improved to maximize statistical power, while minimizing risks to participants. METHODS: Using previously observed dynamics of time to viral rebound (TVR) post-ATI, we modelled estimates for optimal sample size, frequency, and ATI duration required to detect a significant difference in the TVR between control and intervention groups. Groups were compared using a log-rank test, and analytical and stochastic techniques. RESULTS: In placebo-controlled TVR studies, 120 participants are required in each arm to detect 30% difference in frequency of viral reactivation at 80% power. There was little statistical advantage to measuring viral load more frequently than weekly, or interrupting ART beyond 5 weeks in a TVR study. CONCLUSIONS: Current TVR HIV cure studies are underpowered to detect statistically significant changes in frequency of viral reactivation. Alternate study designs can improve the statistical power of ATI trials.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lau JSY, Cromer D, Pinkevych M, et al. Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. J Infect Dis. 2022. PMID: 35104873. doi:10.1093/infdis/jiac032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。